SARS-CoV-1 is a betacoronavirus that caused the 2002–2003 global outbreak, infecting over 8,098 people with 774 deaths (~10% case fatality rate) across 27 countries before containment in July 2003. [1] No known human cases have occurred since 2004. [2] The following is a clinically structured summary.
1. History
- Key HPI: Onset of high fever (>38°C) is the earliest and most universal symptom (97–100% of cases), often with rigors and chills [3-5]
- Cough is typically dry and nonproductive, developing a mean of 4.5 days after fever onset — cough preceding or concurrent with fever argues against SARS [6-7]
- Dyspnea develops in 42–80% of patients, often during the second week of illness [4-5]
- Myalgia (49–70%), malaise (70%), and headache are common early symptoms [4-5]
- Diarrhea occurs in up to 50–66%, typically appearing ~6 days after fever onset [6-7]
- Important negatives: Rhinorrhea is notably rare (<2%) and its presence argues against SARS [4][8]
- Exposure history is critical: close contact with a confirmed/suspected SARS patient within 10 days, or travel to an endemic area [9-10]
2. Alarm Features
- Rapidly progressive respiratory failure during the second week of illness despite decreasing viral load (immunopathologic lung injury) [11]
- Oxygen desaturation (SpO₂ <90%) or increasing oxygen requirements
- Radiographic progression from unifocal to bilateral diffuse opacities suggestive of ARDS [3][12]
- Advanced age (≥60 years), comorbidities, high LDH, and high neutrophil count at admission are independent predictors of mortality [13-14]
- ICU admission rates ranged from 20–38%, with 59–100% of ICU patients requiring mechanical ventilation [13]
- Nosocomial super-spreading events — a single unrecognized case can infect dozens of healthcare workers [11][15]
3. Medications
- No proven specific antiviral therapy exists; all treatments used during the outbreak lacked RCT-level evidence [16]
- Ribavirin was widely used empirically but showed no in vitro activity at achievable concentrations and caused significant toxicity (hemolysis in 76%, hemoglobin drop ≥2 g/dL in 49%) [4][14][16]
- Lopinavir/ritonavir showed the most promising observational data: reduced intubation rates and adverse outcomes when used as initial therapy with ribavirin/steroids [14]
- Pulse methylprednisolone (250–500 mg/day for 3–6 days) was used for "critical SARS" with deteriorating oxygenation, though evidence remains uncontrolled [17-18]
- Interferon-beta and interferon-alfa demonstrated in vitro activity against SARS-CoV but clinical data are limited [11][19]
- Convalescent plasma was used as rescue therapy with anecdotal benefit [18]
- Prolonged high-dose steroids without effective antimicrobials risk disseminated fungal infection and avascular necrosis [17]
4. Diet
- No specific dietary triggers or recommendations unique to SARS
- Hydration is critical, particularly in patients with fever, diarrhea, and increased insensible losses
- Nutritional support for critically ill patients follows standard ICU nutrition protocols
5. Review of Systems
- Respiratory: Cough (dry), dyspnea, chest tightness
- GI: Diarrhea (up to 66%), nausea, vomiting — fecal-oral transmission has been documented [1]
- Constitutional: Fever, rigors, chills, malaise, myalgia, headache
- Notably absent/rare: Rhinorrhea, sore throat, sputum production — their presence lowers SARS probability [7-8][20]
6. Collateral History and Family History
- Exposure history is the single most important epidemiologic factor: contact with confirmed SARS patients, healthcare workers caring for SARS patients, or travel to endemic areas [8][10]
- During the 2003 outbreak, 77–80% of cases were nosocomial (healthcare setting exposure) and 17% were household contacts [4][8]
- Healthcare workers comprised ~28% of all infections [2]
- Family history is not a significant factor; no known genetic predisposition
7. Risk Factors
- Close contact with a SARS patient (household, healthcare, or aerosol-generating procedures) [10][15]
- Healthcare workers — especially those performing intubation, suctioning, or nebulization [10]
- Advanced age (≥60 years): attack rates up to 27.6% in quarantined contacts aged 60–90 [21]
- Comorbidities: diabetes, cardiac disease, chronic lung disease, hepatitis B carrier status [13-14]
- Lack of PPE or inconsistent use of infection control measures [10]
8. Differential Diagnosis
- Community-acquired pneumonia (bacterial, atypical — Mycoplasma, Chlamydia, Legionella): typically presents with productive cough and responds to antibiotics [11]
- Influenza: more likely to have rhinorrhea, sore throat, sputum; higher neutrophil counts; SARS patients had lower leukocyte/neutrophil counts and more ground-glass changes without pleural effusion [22]
- Dengue fever (in endemic areas): distinguished by platelet count <140 × 10⁹/L, WBC <5 × 10⁹/L, and AST >34 IU/L favoring dengue [23]
- MERS-CoV: similar presentation but different epidemiologic exposure (Middle East, camel contact) [24]
- Avian influenza (H5N1): poultry exposure history
- Human metapneumovirus: co-isolated with SARS-CoV in some patients during the outbreak [5]
- Key distinguishing features of SARS: absence of rhinorrhea/sore throat, lymphopenia, no pleural effusion/cavitation/lymphadenopathy, peripheral ground-glass opacities [12][22][25]
9. Past Medical History
- Pre-existing diabetes, cardiovascular disease, chronic hepatitis B, and chronic lung disease increase risk of severe outcomes and mortality [13-14]
- Prior immunosuppression may alter disease course
- No prior episodes expected (novel pathogen in 2002–2003; no cases since 2004)
10. Physical Exam
- Vital signs: High fever (>38°C), tachypnea (RR ≥30 suggests critical disease), tachycardia, hypoxemia on pulse oximetry [13][17]
- Lung exam: Inspiratory crackles and percussion dullness [3][13]
- Notably absent: Pleural effusion signs, upper airway findings (rhinorrhea, pharyngeal erythema are uncommon) [12]
- Physical exam findings are often disproportionately mild relative to radiographic severity early in the course
11. Lab Studies
- Lymphopenia: Present in 54–95% of patients; a hallmark finding [4][6]
- Thrombocytopenia: 28–40% [6]
- Elevated LDH: 58–88% — an independent predictor of poor outcome [4][6][13]
- Elevated AST/ALT: Mildly elevated aminotransferases in the majority [3][6]
- Elevated CK: 18–56% [5-6]
- Hypocalcemia: 60% [4]
- Leukopenia with low neutrophil count (distinguishes from bacterial pneumonia) [22]
- RT-PCR for SARS-CoV: Diagnostic test of choice; sensitivity ~85% from nasopharyngeal/throat swabs, but may be negative early in illness [6][24]
- Serology: Antibody response appears around day 10 — useful for retrospective confirmation, not early diagnosis [11]
12. Imaging
- Chest radiograph (first-line): Abnormal in ~78% at presentation; shows peripheral air-space opacities predominantly in lower lobes [12][26]
- Absent findings: No cavitation, pleural effusion, or hilar lymphadenopathy — their presence argues against SARS [12][25]
- CT chest (more sensitive): Detects disease in patients with normal CXR; shows subpleural ground-glass opacities with air bronchograms, predominantly in posterior lower lobes [3][27]
- Temporal progression: Unifocal → multifocal/bilateral over 7–10 days; peak CT scores at week 2; reticulation/fibrosis may persist after week 4 in ~55% of patients [12][28]
- CT findings resemble bronchiolitis obliterans organizing pneumonia (BOOP) [26]
13. Special Tests
- Clinical prediction rules: A Hong Kong ED-based scoring system using contact history, fever, myalgia, malaise, lymphopenia, thrombocytopenia, and CXR findings achieved AUC of 0.85 for SARS diagnosis [20]
- Symptom scoring: A 6-item clinical score (cough timing relative to fever, myalgia, diarrhea, rhinorrhea/sore throat, lymphopenia, thrombocytopenia) achieved 100% sensitivity and 86% specificity [7]
- RT-PCR (nasopharyngeal swab, stool): Most reliable early diagnostic test, though sensitivity is imperfect early in illness [6]
- Viral culture: Performed in BSL-3 laboratories; not a point-of-care test
- Serology (ELISA, IFA): Useful for epidemiologic confirmation ≥10 days after symptom onset [11]
14. ECG
- No pathognomonic ECG findings for SARS
- ECG should be obtained in patients with tachycardia, hypoxemia, or myocardial injury (elevated CK)
- Monitor for arrhythmias in critically ill patients, particularly those receiving QT-prolonging medications (e.g., ribavirin combinations)
15. Assessment
SARS-CoV-1 presents as a biphasic illness: an initial flu-like prodrome (fever, myalgia, malaise) followed by progressive lower respiratory tract involvement during the second week. [2-3] The hallmark is fever preceding cough by several days, with rapid radiographic progression and lymphopenia. Viral load peaks around day 10, and clinical deterioration during week 2 may be driven by immunopathologic injury rather than uncontrolled viral replication. [11]
- Severity stratification: ~20–38% require ICU admission; overall mortality ~6–10%, rising significantly with age >60 and comorbidities [10][13]
- Complications: ARDS, multiorgan dysfunction, nosocomial super-spreading, long-term pulmonary fibrosis [28-29]
16. Treatment Plan
- Initial stabilization: Supplemental oxygen, IV fluids, antipyretics; monitor SpO₂ closely
- Empiric antibiotics: Broad-spectrum coverage for community-acquired pneumonia (beta-lactam + macrolide or fluoroquinolone) to exclude bacterial etiologies [11]
- Antiviral consideration: Lopinavir/ritonavir (400/100 mg BID) showed the most favorable observational data when initiated early; ribavirin is no longer recommended given toxicity and lack of efficacy [14][16]
- Corticosteroids: Pulse methylprednisolone (250–500 mg/day × 3–6 days) reserved for "critical SARS" with progressive respiratory failure and increasing O₂ requirements [17]
- Rescue therapy: Convalescent plasma or IVIG for refractory cases [18]
- Ventilatory support: Low tidal volume ventilation per ARDS protocol if intubated; NIPPV used cautiously with strict airborne precautions due to aerosolization risk [13][15]
- No approved vaccine exists for SARS-CoV-1 [1]
17. Disposition
- Admission criteria: All suspected/probable SARS cases require hospital admission in airborne isolation (negative-pressure room) with contact precautions [10-11]
- ICU admission: Progressive hypoxemia (SpO₂ <90% on supplemental O₂), respiratory rate ≥30, radiographic progression to bilateral/diffuse disease, hemodynamic instability [13][17]
- Infection control: Standard + Contact + Airborne Precautions (N95 or higher respirator, eye protection, gown, gloves); enhanced precautions during aerosol-generating procedures [10]
- Discharge criteria: Afebrile for ≥4 consecutive days, improving blood work, radiographic improvement, ≥21 days from symptom onset, no supplemental oxygen requirement [30]
- Specialist consultation: Infectious disease, pulmonary/critical care, infection control; public health notification is mandatory [11]
18. Follow-Up / Return Precautions
- Discharged patients should remain home for ≥1 week with a facemask; emphasize hand and toilet hygiene (SARS-CoV detectable in stool for up to 3 weeks post-recovery) [30]
- Follow-up imaging: Serial CXR/CT to monitor for residual pulmonary fibrosis — reticulation persisted in ~55% of patients at 4 weeks [28]
- Return precautions: Recurrence of fever, worsening dyspnea, new or increasing oxygen requirement
- Long-term complications: Avascular necrosis (if prolonged steroids used), pulmonary fibrosis, psychological sequelae [17][28]
- Public health: Contact tracing and quarantine of close contacts for 10–14 days is essential for outbreak containment [11][21]
References
1. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. — Hui DSC, Zumla A. Infectious Disease Clinics of North America. 2019.
2. Coronaviridae—Old friends, new enemy!. — Leao JC, Gusmao TPL, Zarzar AM, et al. Oral Diseases. 2022.
3. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong. — Tsang KW, Ho PL, Ooi GC, et al. The New England Journal of Medicine. 2003.
4. Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. — Christopher M. Booth, MD, Larissa M. Matukas, MD, George A. Tomlinson, PhD, et al JAMA. 2003.
5. Identification of Severe Acute Respiratory Syndrome in Canada. — Poutanen SM, Low DE, Henry B, et al. The New England Journal of Medicine. 2003.
6. Clinical and Laboratory Features of Severe Acute Respiratory Syndrome Vis-a-Vis Onset of Fever. — Liu CL, Lu YT, Peng MJ, et al. Chest. 2004.
7. Predictive Model of Diagnosing Probable Cases of Severe Acute Respiratory Syndrome in Febrile Patients With Exposure Risk. — Chen SY, Su CP, Ma MH, et al. Annals of Emergency Medicine. 2004.
8. Early Diagnosis of SARS: Lessons From the Toronto SARS Outbreak. — Muller MP, Richardson SE, McGeer A, et al. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2006.
9. SARS‐CoV : Lessons learned; opportunities missed for SARS‐CoV ‐2. — Davis IM. Reviews in Medical Virology. 2021.
10. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. — Siegel JD, Rhinehart E, Jackson M, Chiarello L. American Journal of Infection Control. 2007.
11. The Severe Acute Respiratory Syndrome. — Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The New England Journal of Medicine. 2003.
12. Severe Acute Respiratory Syndrome: Radiographic Appearances and Pattern of Progression in 138 Patients. — Wong KT, Antonio GE, Hui DS, et al. Radiology. 2003.
13. Severe Acute Respiratory Distress Syndrome (SARS): A Critical Care Perspective. — Manocha S, Walley KR, Russell JA. Critical Care Medicine. 2003.
14. Treatment and Vaccines for Severe Acute Respiratory Syndrome. — Groneberg DA, Poutanen SM, Low DE, et al. The Lancet. Infectious Diseases. 2005.
15. SARS: Hospital Infection Control and Admission Strategies. — Ho PL, Tang XP, Seto WH. Respirology. 2003.
16. SARS: Systematic Review of Treatment Effects. — Stockman LJ, Bellamy R, Garner P. PLoS Medicine. 2006.
17. Pharmacologic Treatment of SARS: Current Knowledge and Recommendations. — Tai DY. Annals of the Academy of Medicine, Singapore. 2007.
18. Treatment of Severe Acute Respiratory Syndrome. — Lai ST. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2005.
19. Reconsideration of Interferon Treatment for Viral Diseases: Lessons From SARS, MERS, and COVID-19. — Ma D, Wang X, Li M, Hu C, Tang L. International Immunopharmacology. 2023.
20. A Clinical Prediction Rule for Diagnosing Severe Acute Respiratory Syndrome in the Emergency Department. — Leung GM, Rainer TH, Lau FL, et al. Annals of Internal Medicine. 2004.
21. Quarantine Alone or in Combination With Other Public Health Measures to Control COVID-19: A Rapid Review. — Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. The Cochrane Database of Systematic Reviews. 2020.
22. Features Discriminating SARS From Other Severe Viral Respiratory Tract Infections. — Rainer TH, Lee N, Ip M, et al. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2007.
23. Use of Simple Laboratory Features to Distinguish the Early Stage of Severe Acute Respiratory Syndrome From Dengue Fever. — Wilder-Smith A, Earnest A, Paton NI. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2004.
24. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. — Mann R, Perisetti A, Gajendran M, et al. Frontiers in Medicine. 2020.
25. Comparative Study of Patients With and Without SARS Who Fulfilled the WHO SARS Case Definition. — Chang SM, Liu CL, Kuo HT, et al. The Journal of Emergency Medicine. 2005.
26. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. — Lee N, Hui D, Wu A, et al. The New England Journal of Medicine. 2003.
27. Thin-Section CT of Severe Acute Respiratory Syndrome: Evaluation of 73 Patients Exposed to or With the Disease. — Wong KT, Antonio GE, Hui DS, et al. Radiology. 2003.
28. Severe Acute Respiratory Syndrome: Temporal Lung Changes at Thin-Section CT in 30 Patients. — Ooi GC, Khong PL, Müller NL, et al. Radiology. 2004.
29. SARS, MERS and COVID-19: Clinical Manifestations and Organ-System Complications: A Mini Review. — Gerges Harb J, Noureldine HA, Chedid G, et al. Pathogens and Disease. 2020.
30. Patient follow‐up after discharge after COVID‐19 pneumonia: Considerations for infectious control. — Zheng Z, Yao Z, Wu K, Zheng J. Journal of Medical Virology. 2020.